Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07320560

Personalized Atrial Fibrillation Ablation Guided by Non-Invasive Global Mapping

Led by German Heart Institute · Updated on 2026-01-06

45

Participants Needed

5

Research Sites

102 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This pilot study investigates if non-invasive global mapping can guide catheter ablation of atrial fibrillation (AF) by defining personalized targets based on the temporal Stability of local Atrial High-Rate Activity (SAHRA). The study also assesses efficacy and safety of this approach and evaluates potential signals of harm. The main questions it aims to answer are: * Does ablation of targets defined by non-invasive global mapping improve rates of acute atrial fibrillation termination? * Does such a personalized ablation approach reduce arrhythmia recurrence rates? Researchers will compare the results of the personalized ablation approach with comparable patients that had undergone a conventional "empirical" ablation approach (pulmonary vein isolation). Participants will: * Undergo a personalized catheter ablation approach employing both a non-invasive global mapping system and a conventional intracardiac mapping system * Visit the clinic 3, 6 and 12 months after ablation for clinical follow-up * Schedule a telephone visit 9 and 24 months after ablation for clinical follow-up

CONDITIONS

Official Title

Personalized Atrial Fibrillation Ablation Guided by Non-Invasive Global Mapping

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

Ablation-naïve patients with:

  1. Persistent AF planned for catheter ablation plus
  2. Left atrial enlargement (LA diameter ≥45 mm or LA volume index ≥35ml/m2 or LA area ≥20 cm2)
Not Eligible

You will not qualify if you...

  • Previous cardiac ablation
  • Age <18 years
  • Pregnancy or lactation
  • Previous stroke/TIA
  • Severe left ventricular dysfunction (LVEF <35%)
  • Renal failure (GFR <30 ml/min)
  • Dermal disease or hypersensitivity predisposing for skin irritation or exanthema

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

German Heart Center of the Charité, Charité University Hospital Berlin

Berlin, Germany, 10117

Actively Recruiting

2

Frankfurt University Heart and Vascular Center

Frankfurt am Main, Germany, 60598

Not Yet Recruiting

3

Central Lisbon University Hospital Centre (CHULC), Hospital de Santa Marta

Lisbon, Portugal, 1169-024

Not Yet Recruiting

4

Hospital Clinic, University of Barcelona

Barcelona, Spain, 08036

Not Yet Recruiting

5

Gregorio Marañón General University Hospital

Madrid, Spain, 28007

Not Yet Recruiting

Loading map...

Research Team

T

Till F Althoff, M.D.

CONTACT

G

Gerhard Hindricks, M.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here